Clinical trials: Liver and Intrahepatic Bile Duct Disorder
Chronic Hepatitis D Infection
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection.
- Trial name
- NCT06907290
- Testing
- Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg
- Where
- 30 sites in United States, Australia and 9 more
- Volunteers
- 150 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Genotype 1 Chronic Hepatitis C, Treatment Naive
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the effectiveness of telaprevir administered twice daily versus every 8 hours in combination with Peg-IFN-alfa-2a and ribavirin in treatment-naïve participants with chronic HCV genotype 1…
- Trial name
- NCT01241760
- Testing
- Ribavirin, Telaprevir, Pegylated interferon alfa-2a
- Where
- 99 sites in United States, Australia and 11 more
- Volunteers
- 744 people
- Sponsor
- Janssen Infectious Diseases BVBA
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc)
Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
Precision medicine represents a major goal in oncology. It has its underpinning in the identification of biomarkers with diagnostic, prognostic, or predictive values.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Neuroendocrine Tumors
- Trial name
- ELEGANCE (NCT06735560)
- Testing
- 89Zr-TLX250 PET/CT
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Nantes University Hospital
Alcoholic Liver Cirrhosis, Ascites
Prevention of Decompensation in Liver Cirrhosis
The purpose of this study is to determine whether losartan, an angiotensin II blocker prevents the sodium retention in patients with liver cirrhosis and by that reduces the fluid retention.
- Trial name
- NCT00239096
- Testing
- losartan (drug)
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Odense University Hospital
Hepatocellular Carcinoma
Predictive Model for Pain After TACE
The main aim of this study was to analyze the risk factors that helped to predict the pain after transarterial chemoembolization (TACE).This was a prospective observational study enrolled all hepatocellular carcinoma (HCC)…
- Trial name
- NCT05545046
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Yantai Yuhuangding Hospital
Liver Disease
T2 Weighted Imaging of the Liver With Fast Spin Echo MRI
The purpose of this study is to test two new MRI (magnetic resonance imaging) sequences to see how they compare to previously used imaging sequences as they may improve the quality of abdominal MRI.
- Trial name
- NCT02186054
- Testing
- MRI examinations
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Ottawa Hospital Research Institute
Hepatocellular Carcinoma (HCC)
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
Indication: Hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer (BCLC) stage C. Study Objectives: This study aims to use a prospective single-center single-arm pilot approach to preliminarily obtain data on…
- Trial name
- NCT06685354
- Testing
- hepatic arterial infusion of recombinant human type 5 adenovirus
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Henan Cancer Hospital
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT00238394
- Testing
- cediranib maleate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Hepatocellular Carcinoma
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
The investigators hypothesize that vorolanib in combination with checkpoint inhibitors (pembrolizumab for gastric/gastroesophageal (GE) junction cancers and nivolumab for hepatocellular carcinoma (HCC)) may improve immunotherapy…
- Conditions
- Solid Tumor, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03511222
- Testing
- Vorolanib, Nivolumab, Pembrolizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Portal Hypertension, Budd-Chiari Syndrome
Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India
There is a need to re-evaluate the patients classified as NCPH and determine whether the new histological classification proposed by the VALDIG applies to the Indian scenario.
- Conditions
- Portal Hypertension, Budd-Chiari Syndrome, Non-Cirrhotic Portal Hypertension, Porto-Sinusoidal Vascular Diseases
- Trial name
- PSVD-India (NCT06054451)
- Where
- India
- Volunteers
- 210 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Diphtheria, Hepatitis B
Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.
The purpose of the study is to demonstrate consistent results in 3 production lots of Hib-MenAC vaccine when extemporaneously mixed with Tritanrix™-HepB and administered as a single injection, with respect to immunogenicity…
- Conditions
- Diphtheria, Hepatitis B, Haemophilus Influenzae Type b, Whole Cell Pertussis
- Trial name
- NCT00317161
- Testing
- DTPw-HBV/Hib-MenAC conjugate vaccine
- Where
- 3 sites in Thailand
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nonalcoholic Steatohepatitis
Pentoxifylline in Patients With Nonalcoholic Steatohepatitis
One third of the population in the United States has nonalcoholic fatty liver disease (NAFLD). Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, can lead to cirrhosis.Currently, there is no proven therapy for…
- Trial name
- NCT00590161
- Testing
- pentoxifylline (PTX)
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Case Western Reserve University
Hepatic Impairment, Healthy Volunteers
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
- Trial name
- NCT04091061
- Testing
- PF-06865571 100 mg
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis C
Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
This use-results post-marketing surveillance (PMS) study for Sovaldi® tablets (sofosbuvir, SOF) administered in combination with Rebetol® capsules (ribavirin, REB) will evaluate the safety and efficacy of SOF administered in…
- Trial name
- NCT02562742
- Testing
- SOF, REB
- Where
- 45 sites in Japan
- Volunteers
- 554 people
- Sponsor
- Gilead Sciences
Intestinal Failure-associated Liver Disease
Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition
This is a multi-center prospective cross-sectional observational study that will assess the prevalence of liver disease in patients dependent on parenteral nutrition (PN) for 4 or more days per week.
- Trial name
- THRIVE-1 (NCT05011370)
- Where
- 15 sites in United States, Denmark and 2 more
- Volunteers
- 80 people
- Sponsor
- Protara Therapeutics
Hepatocellular Cancer, Chemoembolization
DC Bead LUMI (TM) Loaded With Doxorubicin for Intermediate Hepatocellular Carcinoma (HCC)
The primary purpose of the study is to evaluate the distribution of radiopaque microspheres loaded with doxorubicin in the treatment of unresectable HCC. Prospective, single arm, open label, single centre, pilot study.
- Trial name
- NCT03474354
- Testing
- chemoembolization
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Malagari Katerina
Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy
SIRT and Peri-immunotherapy : a New Concept
The combination of selective internal radiation therapy (SIRT) with immunotherapy represents an innovative and potentially highly effective therapeutic strategy for the treatment of advanced-stage hepatocellular carcinoma (BCLC…
- Trial name
- IMSIRT (NCT06971237)
- Testing
- Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization, Atezolizumab ± Bevacizumab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NASH, NAFLD
Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD
This is a Phase Ib/II, randomized, double-blind, placebo-controlled, international multi-center clinical study to investigate the efficacy and safety of GH509 in subjects with NASH/NAFLD
- Trial name
- NCT05784779
- Testing
- GH509
- Where
- China
- Volunteers
- 180 people
- Sponsor
- 1Globe Biomedical Co., Ltd.
Liver Cirrhosis, Fatty Liver
Multiparametric MR for Rapid Imaging Assessment of the Liver
The RIAL study aims to investigate whether non-invasive measurement of liver fat, iron content and fibrosis are as accurate as liver biopsy specimens in determining if patients have non-alcoholic fatty liver disease (NAFLD) or…
- Trial name
- RIAL (NCT01543646)
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Oxford
Non-Alcoholic Fatty Liver Disease
Lifestyle Guidance Methods in NAFLD
To determine the efficiency of lifestyle modification (due to a dietitian or digital application) compared to standard of care.
- Trial name
- INDIANA (NCT05792488)
- Testing
- Coach, App, Standard of care
- Where
- Belgium
- Volunteers
- 300 people
- Sponsor
- Ziekenhuis Oost-Limburg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.